Target intelligence / Profile preview

CD8+ T cell epigenetic program

Molecular classification
Other, Epigenetic regulation
01

Overview

The CD8+ T cell epigenetic program is the regulatory framework of chromatin modifications and DNA methylation that dictates the functional state of cytotoxic T lymphocytes. During chronic antigen exposure, such as in cancer or chronic viral infections, CD8+ T cells transition from an effector state to an "exhausted" state, a process driven by a stable and distinct epigenetic landscape [3, 4]. This program is characterized by the closing of chromatin at effector gene loci (e.g., IFNG, GZMB) and the opening of regions associated with inhibitory receptors like PD-1 and transcription factors like TOX [1, 2]. Therapeutic intervention seeks to modulate this program using small molecule inhibitors of epigenetic enzymes, such as DNA methyltransferases (DNMTs) or histone methyltransferases (e.g., EZH2), to "reprogram" exhausted cells back toward a functional effector or memory-like phenotype [2, 5]. Successfully targeting this program is a key strategy for overcoming resistance to checkpoint blockade and improving the efficacy of adoptive cell therapies. Key molecular drivers of this program include the HMG-box transcription factor TOX and the nuclear receptor NR4A, which coordinate with epigenetic modifiers to enforce a state of hyporesponsiveness [1]. Unlike transient functional changes, the epigenetic program represents a "molecular scar" that limits the long-term durability of current immunotherapies [3]. Research into this program aims to identify specific enzymatic targets that can be safely inhibited to enhance the metabolic and functional fitness of T cells in the tumor microenvironment. Sources: [1] Khan, O., et al. (2019). TOX is a critical regulator of T cell exhaustion. Nature. [2] Ghoneim, H. E., et al. (2017). De Novo Epigenetic Programs Inhibit T Cell Pluripotency and Restrict Responses to Checkpoint Blockade. Cell. [3] Pauken, K. E., et al. (2016). Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science. [4] Zebley, C. C., et al. (2020). The epigenetic landscape of T cell exhaustion. JCI Insight. [5] Belk, J. A., et al. (2022). Genome-wide CRISPR screens of T cell cytotoxicity reveal novel epigenetic regulators. Nature.

Other names
CD8+ T cell epigenetic landscapeT cell exhaustion epigenetic programCD8+ T cell differentiation programEpigenetic state of CD8+ T cells
02

Mechanism of action

Epigenetic reprogramming via inhibition of DNA methyltransferases (DNMTs), histone deacetylases (HDACs), or histone methyltransferases (e.g., EZH2) to reverse exhaustion-associated chromatin states and enhance T cell persistence and effector function.

03

Biological functions

Immune responseCell differentiationEpigenetic regulationT cell exhaustion
04

Disease associations

CancerInfectionAutoimmune disease
05

Safety considerations

Systemic toxicity due to broad epigenetic modulationRisk of inducing autoimmunityOff-target effects on non-immune cell typesPotential for genomic instability
06

Interacting drugs

Decitabine

4 more in the full profile.

07

Biomarkers

TOX expressionNR4A1 expressionDNA methylation of IFNG promoterChromatin accessibility at PDCD1 locus

Beyond the preview

Go deeper on CD8+ T cell epigenetic program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD8+ T cell epigenetic program.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call